Humana
HUM
390.00
+10.00
+2.63%
Humana
US · HUM
#477 by market cap
Listed 1970
390.00
+10.00
+2.63%
Periodic snapshot; not a real-time feed.
· 2026-11-20 20:01
Quant vs Street three independent views, side by side
StockVane factor grade
C-
Momentum strategy signal
Hold
Analyst consensus
Buy
Mostly aligned, one view stands apart.
Not investment advice. The factor grade ranks this stock on fundamentals against StockVane's covered universe; the momentum strategy signal is a rules-based backtest, not a recommendation; analyst consensus reflects sell-side coverage. The three use different methods and can reasonably disagree.
✦ Quant Analyst Revision Trend how this is computed
Improving
12
■ Upgrades■ Downgrades
- 12 upgrades vs 0 downgrades among tracked analyst rating changes.
- Most recent: TD Cowen moved from Hold to Buy on 2026-11-20.
Analyst consensus 21 analysts
Buy
Avg price target 514.25 +31.9%
Price target rangecurrent 390.00
Low420.00
Avg514.25
High602.00
Buy 76%
Hold 24%
Sell 0%
Recent ratings (25)
| Date | Firm | Analyst | Rating | Target |
|---|---|---|---|---|
| 2026-11-20 | TD Cowen | -- | Buy | 485.00 |
| 2026-11-19 | Morgan Stanley | -- | Hold | 475.00 |
| 2026-11-18 | Bernstein | -- | Buy | 515.00 |
| 2026-11-16 | RBC Capital | -- | Buy | 563.00 |
| 2026-11-15 | Mizuho Securities | -- | Buy | 530.00 |
| 2026-11-12 | Wells Fargo | -- | Buy | 602.00 |
| 2026-11-11 | Mizuho Securities | -- | Buy | 530.00 |
| 2026-11-10 | J.P. Morgan | -- | Hold | 484.00 |
| 2026-11-09 | Piper Sandler | -- | Buy | 526.00 |
| 2026-11-09 | KeyBanc | -- | Hold | -- |
| 2026-11-09 | Deutsche Bank | -- | Buy | 516.00 |
| 2026-11-09 | Barclays | -- | Buy | 587.00 |
| 2026-11-06 | Cantor Fitzgerald | -- | Buy | 495.00 |
| 2026-11-06 | BofA Securities | -- | Buy | 525.00 |
| 2026-11-06 | Guggenheim | -- | Buy | 521.00 |
| 2026-11-06 | Barclays | -- | Buy | 587.00 |
| 2026-11-04 | Bernstein | -- | Buy | 425.00 |
| 2026-10-20 | Guggenheim | -- | Buy | 471.00 |
| 2026-10-14 | Barclays | -- | Buy | 582.00 |
| 2026-10-13 | Mizuho Securities | -- | Buy | 495.00 |
| 2026-10-13 | Evercore | -- | Buy | 480.00 |
| 2026-10-12 | UBS | -- | Hold | 495.00 |
| 2026-10-12 | Raymond James | -- | Buy | 520.00 |
| 2026-10-12 | Truist Financial | -- | Hold | 475.00 |
| 2026-10-09 | Baird | -- | Buy | 596.00 |
Price target trend monthly average, last 3 years
Recent rating changes
| Date | Firm | Change | Target |
|---|---|---|---|
| 2026-11-20 | TD Cowen | Hold → Buy | 485.00 |
| 2026-11-16 | RBC Capital | Hold → Buy | 563.00 |
| 2026-10-12 | Raymond James | Hold → Buy | 520.00 |
| 2026-10-09 | Baird | Hold → Buy | 596.00 |
| 2026-10-07 | Cantor Fitzgerald | Hold → Buy | 460.00 |
| 2026-09-25 | Barclays | Hold → Buy | 515.00 |
| 2026-08-05 | Morgan Stanley | Sell → Hold | 370.00 |
| 2026-07-30 | Leerink Partners | Hold → Buy | 513.00 |
| 2026-07-29 | BofA Securities | Hold → Buy | 500.00 |
| 2026-07-29 | Evercore | Hold → Buy | 480.00 |
| 2026-07-13 | Wells Fargo | Hold → Buy | 502.00 |
| 2026-05-20 | Deutsche Bank | Hold → Buy | 441.00 |
Earnings history price reaction on the day
| Period | Report date | Session | Options expected | Actual move |
|---|---|---|---|---|
| 2026/Q3 | 2026-11-06 | -- | ±8.09% | +5.33% (in line) |
| 2026/Q2 | 2026-07-29 | -- | ±8.36% | -5.99% (in line) |
| 2026/Q1 | 2026-04-29 | -- | ±8.03% | +5.83% (in line) |
| 2025/Q4 | 2026-02-11 | -- | ±9.74% | -3.25% (in line) |
| 2025/Q3 | 2025-11-05 | -- | ±6.96% | -6.01% (in line) |
| 2025/Q2 | 2025-07-30 | -- | ±7.67% | +12.40% (beat) |
| 2025/Q1 | 2025-04-30 | -- | ±9.33% | +1.11% (in line) |
| 2024/Q4 | 2025-02-11 | -- | ±7.34% | -3.55% (in line) |
| 2024/Q3 | 2024-10-30 | -- | ±7.07% | +3.32% (in line) |
| 2024/Q2 | 2024-07-31 | -- | ±6.42% | -10.61% (beat) |
| 2023/Q4 | 2024-01-25 | -- | ±4.93% | -11.69% (beat) |
| 2023/Q3 | 2023-11-01 | -- | ±3.82% | -6.56% (beat) |
"Options expected" is the pre-earnings options market's implied move (a straddle-style estimate), shown next to what actually happened.
Quote time 2026-11-20 20:01:19 · For reference only, not investment advice and not tailored to your situation.
Humana discussion 0 comments